Shares of Neumora Therapeutics, Inc. (NMRA) are slipping over 15% on Monday morning after the phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA).
NMRA is currently trading at $11.40, down $2.16 or 15.89%, on the Nasdaq. The stock opened its trading at $11.07 after closing Friday's trading at $13.56. The stock has traded between $9.35 and $21.00 in the past 52-week period.
Neumora Therapeutics is a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs.
Neumora Therapeutics announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive allosteric modulator (PAM) of the M4 muscarinic receptor and is part of the Company's M4 PAM franchise. The clinical hold determination follows recently available pre-clinical data showing convulsions in rabbits.
Following this action, the Phase 1 single ascending dose / multiple ascending dose study with NMRA-266 has been paused. Approximately 30 participants have been dosed in the Phase 1 study, with no evidence of convulsions observed in any participant.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.